Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology
Determination of a safe dose for nintedanib+nivolumab combination therapy and the generation of exploratory efficacy data in pretreated patients with advanced or metastatic NSCLC of adenocarcinoma histology.
Adenocarcinoma of the Lung
DRUG: nintedanib-nivolumab combination therapy
Safety and tolerability as determined by frequency and severity of adverse events, Safety and tolerability as determined by frequency and severity of adverse events, 47 months|progression free survival, 6-month progression free survival rate, 6 months|progression free survival, 9 month progression free survival rate, 9 months
Overall response rate, Determination of the overall response rate, 35 months|Progression free survival, Determination of progression free survival, 47 months|Time to progression, Determination of the time to progression, 35 months|Overall survival, Determination of the overall survival, 47 months|Adverse events, Determination of adverse events, sevier adverse events, treatment emergent adverse events according to common terminology criteria of adverse events version 4.03, 47 months|Depth of response, Determination of depth of response defined by the maximal tumor shrinkage before progression. Depth of response will be assessed by tumor imaging (computed tomography or magnetic resonance tomography) evaluated according to Response Evaluation Criteria in Solid Tumors version 1.1, 35 months|Time to response, Determination time to response, 35 months
Determination of a safe dose for nintedanib+nivolumab combination therapy and the generation of exploratory efficacy data in pretreated patients with advanced or metastatic NSCLC of adenocarcinoma histology.